生物制剂治疗对降低炎症性肠病中关节炎发生风险的影响
该回顾性队列研究纳入507例克罗恩病或溃疡性结肠炎患者,比较生物制剂与传统改善病情抗风湿药治疗下脊柱关节炎的发生率。结果显示生物制剂使用与脊柱关节炎发生风险降低相关(OR 0.4,95%CI 0.2至0.8),女性、非狭窄非穿透型表型、银屑病及非感染性葡萄膜炎与风险升高相关。
要点
- 生物制剂使用与脊柱关节炎发生风险降低相关(OR 0.4,95%CI 0.2至0.8,校正p=0.01)。
- 女性、非狭窄非穿透型表型、银屑病及非感染性葡萄膜炎与脊柱关节炎风险升高相关。
- 溃疡性结肠炎患者中生物制剂在治疗12个月内对脊柱关节炎发生有保护作用(p=0.03)。
核心结论
- 生物制剂治疗对减少脊柱关节炎的发生有影响,从炎症性肠病向炎症性肠病相关脊柱关节炎转变的临床相关风险因素已显现。
研究设计与样本
- 回顾性队列研究,纳入507例克罗恩病或溃疡性结肠炎患者,分为传统改善病情抗风湿药(cDMARDs)组与生物制剂改善病情抗风湿药(bDMARDs)/靶向合成改善病情抗风湿药(tsDMARDs)组。
- 对出现肌肉骨骼症状的患者进行风湿病学评估,采用多因素分析和Kaplan-Meier曲线评估校正后的脊柱关节炎发生风险。
主要发现
- 克罗恩病患者中,176例接受bDMARDs,112例接受cDMARDs,共诊断106例新发脊柱关节炎;女性(OR 1.7,95%CI 1.1至3,校正p=0.04)、非狭窄非穿透型表型(OR 2,95%CI 1.1至3.4,校正p=0.01)、银屑病(OR 2.1,95%CI 1至4.6,校正p=0.04)及非感染性葡萄膜炎(OR 6.8,95%CI 1.4至33.4,校正p=0.01)与脊柱关节炎发生风险升高相关。
- 克罗恩病患者中,bDMARDs使用具有保护作用(OR 0.4,95%CI 0.2至0.8,校正p=0.01),在整个随访期间统计学上高于cDMARDs(效应量0.47)。
- 溃疡性结肠炎患者中,98例接受b-tsDMARDs,121例接受cDMARDs,共诊断56例新发脊柱关节炎;女性(OR 2.1,95%CI 1至4.3,校正p=0.02)和银屑病(OR 2.7,95%CI 1至6.8,校正p=0.03)与脊柱关节炎发生风险升高相关。
- 溃疡性结肠炎患者中,与cDMARDs相比,bDMARDs在治疗长达12个月内对脊柱关节炎发生具有保护作用(p=0.03)。
关键数值与推荐
- 克罗恩病患者中,bDMARDs使用与脊柱关节炎风险降低相关:OR 0.4(95%CI 0.2至0.8),校正p=0.01。
- 克罗恩病患者中,女性OR 1.7(95%CI 1.1至3,校正p=0.04),非狭窄非穿透型表型OR 2(95%CI 1.1至3.4,校正p=0.01),银屑病OR 2.1(95%CI 1至4.6,校正p=0.04),非感染性葡萄膜炎OR 6.8(95%CI 1.4至33.4,校正p=0.01)。
- 溃疡性结肠炎患者中,女性OR 2.1(95%CI 1至4.3,校正p=0.02),银屑病OR 2.7(95%CI 1至6.8,校正p=0.03);bDMARDs与cDMARDs比较在治疗12个月内保护作用p=0.03。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Evaluate spondyloarthritis (SpA) incidence in inflammatory bowel diseases (IBD) between patients treated with biological disease-modifying antirheumatic drugs (bDMARDs) and conventional DMARDs (cDMARDs) and define risk factors associated with SpA development. METHODS: Retrospective cohort study was conducted on patients with Crohn's disease (CD) or ulcerative colitis (UC) and divided into two cohorts: cDMARDs or bDMARDs/targeted synthetic (ts) DMARDs treated patients. Rheumatological assessment was performed in patients presenting musculoskeletal symptoms. Multivariate analysis and Kaplan-Meier curves were used to evaluate the adjusted SpA risk development. RESULTS: 507 patients were included in the study. 176 patients with CD received bDMARDs, 112 cDMARDs and 106 new SpA diagnosies were formulated. Females (OR 1.7 (95% CI 1.1 to 3), adjusted p=0.04), non-stricturing/non-penetrating phenotype (OR 2 (95% CI 1.1 to 3.4), adjusted p=0.01), psoriasis (OR 2.1 (95% CI 1 to 4.6), adjusted p=0.04) and non-infectious uveitis (OR 6.8 (95% CI 1.4 to 33.4), adjusted p=0.01) were associated with increased SpA risk development, while bDMARDs usage was protective (OR 0.4 (95% CI 0.2 to 0.8), adjusted p=0.01), statistically higher than cDMARDs throughout the entire follow-up (effect size 0.47). 98 patients with UC received b-tsDMARDs, 121 cDMARDs and 56 new SpA diagnoses were formulated. Females (OR 2.1 (95% CI 1 to 4.3), adjusted p=0.02) and psoriasis (OR 2.7 (95% CI 1 to 6.8), adjusted p=0.03) were associated with increased SpA risk development, while bDMARDs were protective for SpA development for up to 12 months of treatment compared with cDMARDs (p=0.03). CONCLUSIONS: bDMARDs treatment had an impact in reducing SpA development and clinical associated risk factors to transition from IBD to IBD-SpA emerged.
引用
- Fatica M, Monosi B, Conigliaro P, et al. Impact of biological therapy in reducing the risk of arthritis development in inflammatory bowel diseases. RMD Open. 2024. PMID: 38296800. doi:10.1136/rmdopen-2023-003820
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。